Is it true that Anticol or other drugs with disulfiram may be effective in treating COVID-19?

At the moment, animal studies are being conducted. There are no clear indications yet that would allow the use of drugs such as Anticol in patients with COVID-19. It is true that a few days ago in the Journal of Experimental Medicine there was an article in which scientists from Weill Cornell Medicine and the Cold Spring Harbor Laboratory (USA) report that disulfiram administered to rodents protects their lungs from immune damage. The results of the study were confirmed in two separate experiments - in animals infected with the SARS-CoV-2 coronavirus and in animals with a syndrome of lung failure called TRALI (acute transfusion lung injury), which in rare cases occurs after a blood transfusion. Tests on Siberian hamsters showed that administration of the drug the day before or the day after SARS-CoV-2 infection led to clearly favorable results. Disulfiram by inhibiting the production of NETs (structures that, driven by disease, can damage lung tissue) blocked progressive damage to lung tissue and vessels, and thus enabled relatively rapid stabilization of lung function and recovery after initial damage. As the researchers emphasize, there is currently no drug that would effectively treat lung damage in patients after COVID-19, so it is worth conducting further research on disulfiram. At the moment, the use of disulfiram in the treatment of COVID-19 is still the subject of research. I also encourage you to read the content of our article, which is constantly updated: https://www.gdziepolek.pl/blog/koronawirus-kiedy-bedzie-lek-i-szczepionka